🔎 Trials Near Me

Почетна › Рак на бели дробови › Вирџинија

Клинички испитувања за Рак на бели дробови во Вирџинија

58 студии за Рак на бели дробови бараат учесници на локации во Вирџинија.

Градови во Вирџинија

Официјален текст на студијата (англиски)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Ballad Health Cancer Care - Bristol, Bristol
  • Augusta Health Center for Cancer and Blood Disorders, Fishersville
  • Centra Alan B Pearson Regional Cancer Center, Lynchburg
  • и уште 7
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04267848

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Virginia Cancer Specialists, Fairfax
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

  • Virginia Cancer Specialists (VCS) ( Site 0408), Fairfax
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06780098

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Chesapeake Regional Medical Center, Chesapeake
  • Augusta Health Center for Cancer and Blood Disorders, Fishersville
  • Bon Secours Memorial Regional Medical Center, Mechanicsville
  • и уште 7
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • VCU Massey Cancer Center at Stony Point, Richmond
  • VCU Massey Comprehensive Cancer Center, Richmond
  • VCU Community Memorial Health Center, South Hill
  • и уште 1
Се регрутираФаза 3
Возраст 70 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • University of Virginia Cancer Center, Charlottesville
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT04181060

Empathic Communication Skills (ECS) Training

  • Chesapeake Regional Healthcare (Data Collection Only), Chesapeake
Се регрутираДобредојдени се здрави волонтери
Возраст од 18 до 100 · Сите полови · Ажурирано 1.10.2026 · NCT05456841

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Hematology Oncology Associates of Fredericksburg Inc, Fredericksburg
  • Centra Alan B Pearson Regional Cancer Center, Lynchburg
  • Virginia Cancer Institute, Richmond
  • и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06498635

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  • Virginia Cancer Specialists, Fairfax
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT06765109

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Virginia Cancer Specialists, Fairfax
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT06881784

A Study of PHN-012 in Patients With Advanced Solid Tumors

  • PHN-012-001 Site, Fairfax
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07127874

Phase 1 Study of PF-08046033 in Advanced Solid Tumors

  • Inova Schar Cancer Infusion Pharmacy, Fairfax
  • Inova Schar Cancer, Fairfax
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07519655

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • UVA Comprehensive Cancer Center, Charlottesville
  • UVA Health Fontaine Research Park, Charlottesville
  • University of Virginia, Charlottesville
  • и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07222566

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  • Virginia Commonwealth University, Richmond
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07063745

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, Fairfax
Се регрутираФаза 2
Возраст од 18 до 95 · Сите полови · Ажурирано 23.9.2026 · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Virginia Cancer Specialists - Arlington, Arlington
  • Virginia Cancer Specialists, Fairfax
  • VCU Massey Cancer Center, Richmond
  • и уште 1
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06712316

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  • NEXT Oncology Virginia, Fairfax
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06128551

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  • University of Virginia Health System, Charlottesville
  • Virginia Commonwealth University (Vcu), Richmond
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07100080

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

  • Next Oncology Virginia Cancer Specialist, Fairfax
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT07629960

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

  • NEXT - Virginia, Fairfax
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07349537

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

  • University of Virginia Cancer Center, Charlottesville
  • VCU Massey Comprehensive Cancer Center, Richmond
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT06287775

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

  • Virginia Cancer Specialists, Fairfax
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07625644

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • NEXT Virginia, Fairfax
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT05786924

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Virginia Cancer Specialists, Fairfax
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 10.9.2026 · NCT06293898

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • Virginia Oncology Associates, Norfolk
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06793215

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • University of Virginia Health System, Charlottesville
  • USO - Virginia Cancer Specialists, Fairfax
  • VCU Health Adult Outpatient Pavillion, Richmond
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06119581

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

  • USO-Virginia Cancer Specialists, PC, Fairfax
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 8.9.2026 · NCT06561685

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

  • University of Virginia Cancer Center, Charlottesville
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 4.9.2026 · NCT07012031

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

  • Avenzo Therapeutics Recruiting Site, Fairfax
Се регрутираФаза 1/2
Возраст од 18 до 75 · Сите полови · Ажурирано 4.9.2026 · NCT07038343

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • NEXT Oncology, Fairfax
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT06343402

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Sentara Martha Jefferson Hospital, Charlottesville
  • Inova Schar Cancer Institute, Fairfax
  • Inova Fair Oaks Hospital, Fairfax
  • и уште 5
Се регрутираДобредојдени се здрави волонтери
Возраст од 45 до 75 · Сите полови · Ажурирано 2.9.2026 · NCT06995898

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  • University of Virginia, Charlottesville
  • Virginia Cancer Specialists, Fairfax
  • Shenandoah Oncology, P.C., Winchester
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 1.9.2026 · NCT07185997

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  • Virginia Cancer Specialists, Fairfax
  • Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg
  • Virginia Commonwealth University School of Medicine, Richmond
  • и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 1.9.2026 · NCT06712355

Health Education Approach to Lung Screening

  • Virginia Commonwealth University, Richmond
Се регрутираДобредојдени се здрави волонтери
Возраст од 50 до 80 · Сите полови · Ажурирано 25.8.2026 · NCT06070870

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • Inova Alexandria Hospital, Alexandria
  • Inova Schar Cancer Institute, Fairfax
  • Inova Fair Oaks Hospital, Fairfax
  • и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT06500481

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • NEXT Oncology - Virginia Cancer Specialists, Fairfax
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 5.8.2026 · NCT07444814

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • NEXT Virginia, Fairfax
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 15.7.2026 · NCT05652686

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

  • NEXT Virginia, Fairfax
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 9.7.2026 · NCT07315113

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • NEXT Oncology Virginia, Fairfax
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 30.6.2026 · NCT06162221

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

  • NEXT Virginia, Fairfax
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 29.6.2026 · NCT07458347

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.